Analysts have clear opinions on SUPN.

There are 3 analysts on the Wall offering 12 month price targets for Supernus Pharmaceuticals in the last 3 months. The average price target is $24.00 with a high forecast of $25.00 and a low forecast of $23.00. The average price target represents a -0.87% decrease from the last price of $24.21.
Supernus Pharmaceuticals, Inc. (SUPN) is followed by 3 analysts on the street.

Annabel Samimy from Stifel Nicolaus rates it a Hold with a target of $25.00.

Similarly, 2 months ago Patrick Trucchio of Berenberg Bank Downgraded a Hold with a target of $24.00.

The consensus on the street is Hold.

What does Supernus Pharmaceuticals, Inc.(SUPN) do ?
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Supernus Pharmaceuticals, Inc. (SUPN) Insider Trades

Multiple company employees have indulged in significant insider trading. Supernus Pharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Pres, CEO, Khattar Jack A. : P – Purchase(+$189,982) of SUPN in the trading session of 2019-08-23.

SVP, CFO Patrick Gregory S : S – Sale+OE(-$830,650) of SUPN in the trading session of 2019-02-27.

VP, CFO Patrick Gregory S : S – Sale+OE(-$1,981,914) of Supernus Pharmaceuticals, Inc. in the trading session of 2018-07-02.

Looking for stocks just like SUPN?

Based on Wall Street analyst research, several stocks are similar to SUPN
They are:
– MRNS [Info can be found here: ]
– CTLT [Info can be found here: ]
– ADMS [Info can be found here: ]